Patient-Centered Management in BRAF-Positive Metastatic Melanoma

Introduction

BRAF/MEK Inhibitor Combinations: Dabrafenib/Trametinib (COMBI-d)

COMBI-d Trial Updates Outcomes

COMBI-d Trial Updates Genomic Analysis

BRAF/MEK Inhibitor Combinations: Vemurafenib/Cobimetinib (coBRIM)

coBRIM Trial Update Outcomes

coBRIM Trial Update Predictors of Response

Single-Agent BRAF Inhibitor Advice From the Experts

First-Line Therapy Targeted Therapy or Immunotherapy?

Patient Selection for BRAF/MEK Therapy Expert Opinion

Patient Selection for BRAF/MEK Therapy

Additional Questions

AEs of BRAF/MEK Therapy

AEs of BRAF/MEK Therapy (cont)

AEs of BRAF/MEK Therapy (cont)

Which Combination to Choose?

Shared Decision-Making

Collaborating With Patients

Strategies for Better Communication

Working Across Specialties

Patient-Physician Communication

Concluding Remarks

Abbreviations